Sanofi will invest more than €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France as part of a €3.5 billion programme in the country. The latest ...
Bloomberg on MSN3mon
France to Formally Screen CD&R Purchase of Sanofi Unit: FigaroThe division sells over-the-counter medications, including pain reliever Doliprane, which is the most-used drug in France.
France 24 on MSN3mon
Sanofi pursues sale of France's leading painkiller to US investment fund after controversyThe sale of a controlling 50-percent stake in Opella to CD&R values the maker of France's leading painkiller, Doliprane, at ...
Deux autres sites vont bénéficier, dans une moindre mesure, de ce nouvel investissement de 1,1 milliard d’euros, « historique » pour la France selon Sanofi, et qui « court jusqu’à horizon 2030 », a ...
Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...
provoquant un nombre exceptionnellement élevé d'hospitalisations comparé aux saisons précédentes, observe Santé publique France.
L’Etat avait une part de responsabilité dans l’« insuffisance d’information » donnée aux patients et aux médecins sur les ...
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback